pharmaceutical formulation, methods for determining whether T cells recognize a polypeptide, for treating an individual against alternaria and / or cladosporium allergy or for preventing an individual for alternaria and / or cladosporium allergy, and for preparing a pharmaceutical formulation of the invention, use of at least three polypeptides or salts, and polypeptide or salt

摘要

1/2 summary “pharmaceutical formulation, methods to determine if t cells recognize a polypeptide, to treat an individual against alternaria and / or cladosporium allergy or to prevent allergy in an individual alternaria and / or cladosporium, and to prepare a pharmaceutical formulation of the invention, use of at least three polypeptides or salts, and polypeptide or salts, which are described as pharmaceutical formulations. may be used to prevent or treat allergy to alternaria and / or cladosporium molds, comprising a pharmaceutically acceptable carrier or diluent and a pharmaceutically acceptable salt or polypeptide thereof selected from at least three: (a) a polypeptide comprising the wswkigpaiatgnt amino acid sequence (alt28; seq id no: 101) or a t-cell epitope-containing variant sequence derived from said amino acid sequence or a salt thereof; (b) a polypeptide comprising the amino acid sequence of kyrrvvragvkvaqtar (alt34a; seq. id: 107) or a variant t-cell epitope-containing sequence derived from said amino acid sequence, or said salt thereof; (c) a polypeptide comprising the amino acid sequence of kyagvfvstgtlggg (sequence id: 112) or a variant t-cell epitope-containing sequence derived from said amino acid sequence, or said salt thereof; (d) a polypeptide comprising the amino acid sequence of aevyqklkalakktygq (alt13a; sequence id: 83) or a variant t-cell epitope-containing sequence derived from said amino acid sequence, or said salt thereof; (e) a polypeptide comprising the amino acid sequence of slgfnikatnggtld (alt01a; seq id: 60) or a variant t-cell epitope-containing sequence derived from said amino acid sequence, or said salt thereof; (f) 2/2 a polypeptide comprising the amino acid sequence of sakrmkvafkldiek (alt06; sequence id: 72) or a variant sequence containing t cell epitope derived from said amino acid sequence, or said salt of this; (g) a polypeptide comprising the dityvatatlpnycr amino acid sequence (sequence id: 111) or a t-cell epitope-containing variant sequence derived from said amino acid sequence, or a salt thereof; and (h) a polypeptide comprising the amino acid sequence of gwgvmvshrsget (alt14; seq id: 84) or a variant t-cell epitope-containing sequence derived from said amino acid sequence, or said salt thereof; wherein a variant t-cell epitope-containing sequence of said amino acid sequence is said amino acid sequence with up to seven amino acid modifications, each of which is independently a deletion. Replacement, or insertion, and each polypeptide is up to 30 amino acids in length.